A phase II study of the combination of liposomal doxorubicin (LD) and gemcitabine (G) in patients with relapsed ovarian cancer after chemotherapy containing platinum compounds.

被引：0
|
作者：
Gambino, A [1 ]
Tognon, G [1 ]
Galleri, G [1 ]
Agoni, L [1 ]
Pecorelli, S [1 ]
机构：
[1] Univ Studi, Brescia, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：492S / 492S
页数：1
相关论文
共 50 条
  • [21] Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer
    Verschraegen, C. F.
    Czok, S.
    Muller, C. Y.
    Boyd, L.
    Lee, S. J.
    Rutledge, T.
    Blank, S.
    Pothuri, B.
    Eberhardt, S.
    Muggia, F.
    ANNALS OF ONCOLOGY, 2012, 23 (12) : 3104 - 3110
  • [22] Brain metastases in relapsed epithelial ovarian cancer after chemotherapy with pegylated liposomal doxorubicin
    Kasprowicz, Nikola Serena
    Fotopoulou, Christina
    Oskay-Oezcelik, Guelten
    El Khalfaoui, Khalid
    Boehmer, Dirk
    Sehouli, Jalid
    ANTICANCER RESEARCH, 2008, 28 (3B) : 1943 - 1946
  • [23] Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study
    Skarlos, DV
    Kalofonos, HP
    Fountzilas, G
    Dimopoulos, MA
    Pavlidis, N
    Razis, E
    Economopoulos, T
    Pectasides, D
    Gogas, H
    Kosmidis, P
    Bafaloukos, D
    Klouvas, G
    Kyratzis, G
    Aravantinos, G
    ANTICANCER RESEARCH, 2005, 25 (04) : 3103 - 3108
  • [24] Skin toxicity after palliative chemotherapy containing pegylated liposomal doxorubicin for ovarian cancer patients
    Nowara, Elzbieta
    Huszno, Joanna
    ANNALS OF PALLIATIVE MEDICINE, 2013, 2 (02) : 71 - 75
  • [25] Trabectedin in combination with pegylated liposomal doxorubicin: A retrospective analysis in patients with platinum-sensitive relapsed ovarian cancer.
    Nicoletto, Maria Ornella
    Baldoni, Alessandra
    Casarin, Alessandra
    Nardin, Margherita
    Baretta, Zora
    Randon, Giovanni
    Lardelli, Pilar
    Nieto, Antonio
    Alfaro, Vicente
    Rigamonti, Claudia
    Conte, Pier Franco
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] A phase II study of gemcitabine (G) in combination with liposomial doxorubicin (LD) for hepatocellular carcinoma (HCC) otherwise untreatable
    Pastorelli, D.
    Cartei, G.
    Zustovich, F.
    Ceravolo, R.
    Zovato, S.
    Farinati, F.
    Murrone, A.
    Zanus, G.
    Binato, S.
    Cillo, U.
    ANNALS OF ONCOLOGY, 2005, 16 : 158 - 158
  • [27] Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer
    Mo, Dun-Chang
    Ren, Tao
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (05) : 522 - +
  • [28] Pegylated liposomal doxorubicin (PLD) and gemcitabine (G) in metastatic breast cancer (MBC) patients: A phase II study.
    Fabi, A
    Papaldo, P
    Ciccarese, M
    Salesi, N
    Lorusso, V
    Ferretti, G
    Carlini, P
    Sacchi, I
    Cecere, F
    Cognetti, F
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 80S - 80S
  • [29] A phase I/II study of maplirpacept in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer (OC): Phase 1 results
    Street, Daron G.
    Kuttschreuter, Luke
    Starks, David
    Mahdi, Haider
    Linn, Carlos
    Pavlov, Dmitri
    Peguero, Julio Antonio
    Chawla, Sant P.
    Bruns, Ingmar
    Waggoner, Steven E.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
    Mutch, David G.
    Orlando, Mauro
    Goss, Tiana
    Teneriello, Michael G.
    Gordon, Alan N.
    McMeekin, Scott D.
    Wang, Yanping
    Scribner, Dennis R., Jr.
    Marciniack, Martin
    Naumann, R. Wendel
    Secord, Angeles Alvarez
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (19) : 2811 - 2818
12345